{"id":"NCT02770365","sponsor":"Padagis LLC","briefTitle":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05","primaryCompletion":"2016-11","completion":"2016-11","firstPosted":"2016-05-12","resultsPosted":"2020-08-11","lastUpdate":"2021-11-02"},"enrollment":695,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atrophy"],"interventions":[{"type":"DRUG","name":"estrace cream (Perrigo)","otherNames":["Perrigo product"]},{"type":"DRUG","name":"estrace cream (Reference)","otherNames":["Reference Listed Drug product"]},{"type":"DRUG","name":"Placebo cream","otherNames":[]}],"arms":[{"label":"Test Product","type":"EXPERIMENTAL"},{"label":"Reference Product","type":"ACTIVE_COMPARATOR"},{"label":"Placebo product","type":"PLACEBO_COMPARATOR"}],"summary":"To compare safety and efficacy of Perrigo's drug product compared to an FDA approved drug product in the treatment of vulvar and vaginal atrophy.","primaryOutcome":{"measure":"Percentage of Subjects Identified as Responders","timeFrame":"Day 8","effectByArm":[{"arm":"Test Product","deltaMin":36.8,"sd":null},{"arm":"Reference Product","deltaMin":32,"sd":null},{"arm":"Placebo Product","deltaMin":0.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"30 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":277},"commonTop":[]}}